This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The current consumer price inflation in Europe and the United States is less than 2%, compared to India's double digit inflation. The Pepsi and Coca-Cola example is meaningless in the context of Indian beverage market. More competition is lacking because of limited demand. Indian consumer has limited interest in soft drinks. Soft drinks represent less than 5% of Indian beverage market. Indian consumers prefer milk-based, tea and coffee and these account for 90% of Indian beverage market, with plenty of competing domestic brands and even European brands like Nestlé. The next most important market in India is bottled water, which outsells the combined soft drink sales of the Pepsi and Coca-Cola. Organised retail too will have numerous brands and strong competition. Comparing the 21st century to the 18th century is inappropriate. Conditions today are different. India wasn't a democracy then. Global awareness and news media have also changed. For example, China has over 57 million square feet of retail space owned by foreigners, employing millions of Chinese citizens. Yet, China hasn't become a vassal of imperialists, enjoying respect from all global powers. Other Asian countries like Malaysia, Taiwan, Thailand and Indonesia see foreign retailers as catalysts of new technology and price reduction; and they have benefited by welcoming FDI in retail. India too will benefit by integrating with the world, rather than isolating itself. With 51% FDI limit in multi-brand retailers, nearly half of any profits will remain in India.
The British government did not recognize the settlement as a colony for fear of provoking a Spanish attack. This delay in government oversight enabled the settlers to establish their own laws and forms of government. During this period, a few settlers gained control of the local legislature, known as the Public Meeting, as well as of most of the settlement's land and timber. The British did not appoint their first superintendent over the Belize area until 1786. Throughout the 18th century, the Spanish attacked Belize every time war broke out with Britain. The Battle of St. George's Caye was the last of such military engagements, in 1798, between a Spanish fleet and a force of Baymen and their slaves. From 3 to 5 September, the Spaniards tried to force their way through Montego Caye shoal, but were blocked by defenders. Spain's last attempt occurred on 10 September, when the Baymen repelled the Spanish fleet in a short engagement with no known casualties on either side. The anniversary of the battle has been declared a national holiday in Belize and is celebrated to commemorate the "first Belizeans" and the defence of their territory taken from the Spanish empire.
== Diagnosis == There is no consensus standard for diagnosing carpal tunnel syndrome. A combination of characteristic symptoms (how it feels) and signs (what the clinician finds on exam) is associated with a high probability of CTS without electrophysiological testing. Sensation loss can be established using Semmes-Weinstein monofilament testing. CTS can be detected on examination using one of several maneuvers to provoke paresthesia (a sensation of tingling or "pins and needles" in the median nerve distribution). These so-called provocative signs include:
== C == Cadiot–Chodkiewicz coupling Cadogan-Sundberg indole synthesis Camps quinoline synthesis Cannizzaro reaction Carbohydrate acetalisation Carbonyl reduction Carbonylation Carbylamine reaction Carroll reaction Castro–Stephens coupling Catalytic reforming Catellani Reaction Corey–Itsuno reduction (AKA Corey–Bakshi–Shibata reduction or CBS reduction) Chan–Lam coupling Chapman rearrangement Cheletropic reaction Chichibabin pyridine synthesis Chichibabin reaction Chiral pool synthesis Chugaev elimination (also transliterated as Tschugajeff reaction) Ciamician–Dennstedt rearrangement Claisen condensation Claisen rearrangement Claisen–Schmidt condensation Clemmensen reduction Collins reagent Combes quinoline synthesis Conia reaction Conrad–Limpach synthesis Cook–Heilbron thiazole synthesis Cope elimination Cope rearrangement Corey reagent Corey–Fuchs reaction Corey–Gilman–Ganem oxidation Corey–Kim oxidation Corey-Nicolaou macrolactonization Corey–Posner, Whitesides–House reaction Corey-Seebach reaction Corey–Winter olefin synthesis Corey–Winter reaction Cornforth rearrangement Coupling reaction Crabbé reaction Craig method Cram's rule of asymmetric induction Creighton process Criegee reaction Criegee rearrangement Cross metathesis Crum Brown–Gibson rule Curtius degradation Curtius rearrangement, Curtius reaction Cyanohydrin reaction
=== Vascularization === It is necessary for a network of blood vessels to be established as soon as possible to provide the growing tissue with nutrients, to take away cellular wastes, and transport new leukocytes to the area. Fibroblasts, the main cells that deposit granulation tissue, depend on oxygen to proliferate and lay down the new extracellular matrix. In vascularisation, also called angiogenesis, endothelial cells quickly grow into the tissue from older, intact blood vessels. These branch out in a systematic way, forming anastomoses with other vessels.
Sources: en.wikipedia.org
== Treatment == Treatment for CLSD is largely focused on treating the symptoms of the disorder, because it is still in the early stages of research. Symptomatic treatment is also the only option due to the genetic nature of the disorder. Treatment may include surgeries to correct facial and cranial dysmorphisms or therapy sessions to help alleviate behavioral abnormalities associated with the disorder.
However, new kits such as "NETSPOT" for more rapidly preparing Ga-68 edotreotide or DOTATATE from Ga-68(III) ions have increased the flexibility of sourcing of this radiopharmaceutical for Ga-68 endocrine receptor (octreotide) scans. With NETSPOT the preparation of the Ga-68 DOTATATE is immediate once the Ga-68 has been acquired from the generator and mixed with the reagent.
=== Mechanism of Action === In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite allantoin with carbon dioxide and hydrogen peroxide as byproducts in the chemical reaction.
This could be due to their shorter generation time, higher metabolic rate, increased population structuring, increased rate of speciation, or smaller body size. When studying ancient events like the Cambrian explosion under a molecular clock assumption, poor concurrence between cladistic and phylogenetic data is often observed. There has been some work on models allowing variable rate of evolution. Models that can take into account variability of the rate of the molecular clock between different evolutionary lineages in the phylogeny are called "relaxed" in opposition to "strict". In such models the rate can be assumed to be correlated or not between ancestors and descendants and rate variation among lineages can be drawn from many distributions but usually exponential and lognormal distributions are applied. There is a special case, called "local molecular clock" when a phylogeny is divided into at least two partitions (sets of lineages) and a strict molecular clock is applied in each, but with different rates.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.